HCC is the fifth most common tumor throughout the world
incidence is increasing worldwide because of the spread of infections caused by the hepatitis B and C viruses
Surveillance programs have been developed for patients with cirrhosis, and this approach is associated with annual HCC detection rates ranging from 3% to 8%
Conventional approaches, such as systemic chemotherapy and radiation, have proved to be ineffective in HCC
Sorafenib may be associated with slightly improved survival in patients with advanced HCC